Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma

The therapeutic options for HCC include hepatectomy, liver transplantation, local ablation therapy, transarterial chemoembolization (TACE), radiotherapy, and systemic therapy. However, as early-stage HCC often presents with no obvious symptoms or atypical clinical manifestations, over 80% of patients are diagnosed at an advanced stage, losing the opportunity for surgical resection and leaving liver transplantation as the only potentially curative option. Nevertheless, even after liver transplantation, the recurrence rate of HCC remains as high as 30-45%. In recent years, with the successive la

Trial Details

NCT ID
NCT07077356
Phase
PHASE1
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • HBV mRNA vaccine
Locations (sample)
  • Chengdu, China|30.66667,104.06667

Key Eligibility Criteria

  • Male or female patients aged ≥18 years;
  • Patients with histologically, cytologically, or clinically diagnosed hepatocellular carcinoma (HCC);
  • Patients who, based on the investigator's assessment, meet the indications for liver transplantation and have expressed willingness to undergo tran…
  • Positive for hepatitis B surface antigen (HBsAg) in peripheral blood;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →